

Discarded Drug Program Webinar

December 5, 2024

Welcome



Thank you for joining our **Discarded Drug Program** webinar.

- This session will be recorded and posted.
- Participants can submit questions via the Q&A feature.
- This is approximately a one-hour session with time for questions at the end.



Торіс	Presenter			
Introductory Remarks	Mark Bremer, CMS			
Discarded Drug Program Overview	Katie Wilder, Contractor			
Refund Calculations and Timeline	Katie Wilder, Contractor			
Manufacturer Payment Portal Overview	TPA Representative, Contractor			
Available Resources	Katie Wilder, Contractor			
Q&A Session	Suzanne Bromley, Contractor			
Closing Remarks	Mark Bremer, CMS			

Goals




- Provide an overview of the Discarded Drug Program
- Demonstrate how to:
 - Access Discarded Drug Refund Reports in the Manufacturer Payment Portal (MPP)
 - Pay any refund amounts due in MPP
- Answer your Discarded Drug Program questions

Discarded Drug Program

Section 90004 of the Infrastructure Investment and Jobs Act (2021) requires manufacturers to provide a refund to CMS for the discarded amounts from drugs that meet certain criteria.

Manufacturers who fail to comply with the requirement under <u>42 CFR §</u> <u>414.940(b)</u> will be subject to a Civil Monetary Penalty (CMP) equal to the sum of 125 percent of the assessed refund obligation.



Definition of Refundable Drug

Inclusion Criteria

- Single-source drug or biological, including biosimilars
- Must be furnished from a single-use package or single-dose container
- All national drug codes (NDCs) assigned to the drug's billing and payment code must be single-dose, as described in each product's labeling
- Payment is made under Medicare Part B

Exclusion Criteria

- Radiopharmaceutical (therapeutic or diagnostic) or imaging agents
- Certain drugs or biologicals requiring filtration during preparation (prior to dilution and administration) for which unused portions must be discarded after the filtration process
- Drugs or biologicals approved or licensed by the FDA on or after November 15, 2021, until the last day of the sixth full quarter for which the drug has been marketed (as reported to CMS) for the first reported sale for any NDCs of such drug

Tracking Discarded Drug Units

History



- Effective January 2017, providers and suppliers are required to report the JW modifier on all claims that bill for drugs and biologicals separately payable under Medicare Part B with unused and/or discarded amounts.
- Starting in July 2023, the JZ modifier was added to track all such drugs with no discarded amounts.

Definitions

_	
	- 7

- **Discarded amount**: Any amount of drug that is not a part of the dose and is not intended to have a therapeutic effect in the patient, up to the amount identified on the FDA-approved label.
- JW Modifier: Used on a Medicare Part B claim to denote the portion of the drug that was discarded.
- JZ Modifier: Used on a Medicare Part B claim to indicate no portion of the drug was discarded.


Applicable Percentages

An applicable percentage is essentially the **discarded amount threshold** for a specific drug. The applicable percentage is used in the calculation of the refund amount due from manufacturers. It is required to be at least **10%**, but can be increased through noticeand-comment rulemaking for drugs with unique circumstances.

The following are increased applicable percentages for drugs with unique circumstances:

- 35% Drug reconstituted with a hydrogel and has variable dosing based on patient-specific characteristics
- 90% Low volume dose drug contained within 0.1 mL or less
- 45% Low volume dose drug contained within 0.11 mL up to 0.4 mL
- 26% Designated orphan drugs under Section 526 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) that are furnished to fewer than 100 unique beneficiaries per calendar year

Calculation




Manufacturer Refund Due Total Number of Discarded Drug Units (JW units on claims data) ASP Payment Limit Applicable Percentage Multiplied by Estimated Total Allowed Charges

Refund Calculation when Refundable Drugs have Multiple Manufacturers

Labeler Name	Billing Units Sold	Proportion of Units Sold	Refund Due Per Manufacturer
Labeler A	5,000	50%	\$5 <i>,</i> 000.00
Labeler B	1,500	15%	\$1,500.00
Labeler C	3,500	35%	\$3,500.00
Total	10,000	100%	\$10,000.00

Initial Report Timeline



Onboarding Process

P Number Assignment

- A P Number is a unique identifier used in the Health Plan Management System (HPMS) to identify manufacturers and create accounts.
- Many manufacturers already have a P Number for participation in other programs, but some need a P Number issued for the Discarded Drug Program.
- Once a P Number is issued, a representative from the Third-Party Administrator (TPA) Support Center, Palmetto GBA, will contact the manufacturer.



- Manufacturers must designate their Program Type (Part B or Part B and Part D) and provide contact information for a Discarded Drug Program Contact in HPMS.
- Manufacturers must ensure that the Discarded Drug Program Contact information in HPMS is accurate at all times.



Manufacturer Payment Portal (MPP) Access

- TPA will use the Discarded Drug Program contact information collected in HPMS to assign manufacturer user access to the MPP.
- The Discarded Drug Program contact will be able to access reports and initiate payment for refunds due.
- The link to the new portal will be located on the home page of the TPA website (<u>www.tpadministrator.com</u>).

Requesting a P Number

Email <u>DiscardedDrugs@cms.hhs.gov</u>

- Manufacturer Legal Name
- Data Universal Numbering System (DUNS) Number
- Employer Identification Number (EIN)
- Primary Contact First and Last Name
- Primary Contact Email Address
- Primary Contact Phone Number
- Subject Line of the Email Should Read "[Manufacturer Name] Request for P Number"

TPA Website



Programs -Listservs -

Search for...

٩

Welcome to the Third Party Administrator (TPA)

On this site, you will be able to access the Manufacturer Payment Portal (MPP) along with finding information and resources for the following programs:

- Coverage Gap Discount Program (CGD)
- Discarded Drug Program (DDP)
- Manufacturer Discount Program (MDP)
- Medicare Prescription Drug Inflation Rebate Program (Inflation Rebates)

The TPA website is the payment gateway for manufacturers participating in one or more discount or rebate programs listed.




Portal (MPP) Login

Accessing MPP

elcome to the Manufact	urer Payment Portal	Log in			
	ateway to programs administered by the Third Party Administrator (TPA) for the Centers for Medicare & (SSO) and role-based responsibilities, authorized users can access the following programs:	Don't have an account? User ID *	Create account		ו
		Password *			
		Enter Your Password		Ø	
		Login Forgo	t Password?		
Discarded Drug Program (DDP) The Discarded Drug Program, created in response to Section 90004 of the Infrastructure Investment and Jobs Act (Pub. L. 117-58, November 15, 2021) which amended section 1847A of the Social Security Act. requires manufacturers to provide a refund to CMS for certain discarded amounts from a single dose container or single-use package drug.					
CMS will issue annual reports, with the TPA facilitating the report publishing and payment processes for refund amounts due.					

Landing Page - No Reports



My Profile (1 of 2)

	TPAdministrator.com	Contact Us	My Profile Log Out Logged in as MO578408
Overview Discarded Drug Program			
Manufacturer Paymer Welcome M	_	Profile	2
Change Password	ii Update PIN		
Discard Drug			
Company Ii Banking Inf Roles & Ac	ormation		
View Pr	ofile		

My Profile (2 of 2)

	INTER					TPA	Administrator.co	om Contact Us	M	y Profile Log (Logged in as MO578	
Overview	Disc	arded Drug Program									
Discardeo	d Dru	ıg Program	- My	/ Profile							
Profile Home > Dis	scarded D	rug Program									
Organization Inforr Name: UAT Parent Org Type: Manufacturer	5 Requ	iest Payer Account M	odificat	tion							
Associated Co	ompany	/ EFT Information									
Associated Co	ompany			Status		Begin Quarte	r	Paver Routing #		Paver Account #	
Associated Co Company ID	ompany ~	Name	~	Status All	~	Begin Quarte	r ~	Payer Routing #	~	Payer Account #	~
Company ID All Show 10 v entr	×	Name All	~	All		All	~	AII		All Filter R	✓
Company ID All Show 10 v entr Company Id	v ies ≹	Name All Name	~	All Status	∳ Beg	All in Quarter	✓✓Payer	All Routing #	Pay	All Filter R er Account #	
Company ID All Show 10 v entr	v ies ≹	Name All	~	All		All in Quarter	~	All Routing #	Pay	All Filter R	
Company ID All Show 10 v entr Company Id	ies	Name All Name	~	All Status	∳ Beg	All in Quarter 304	✓✓Payer	AII Routing #	Paye ****	All Filter R er Account #	

Landing Page - Reports Available

CENTER FOR MEDICARE A MEDICADE MEDICARE	TPAdministrator.com	Contact Us	My Profile Log Out Logged in as MO578408
Overview Discarded Drug Program			
Manufacturer Payment Portal			
Discarded Drug Program			
Refund Report(s) available.			
View Reports			
Disclaimer Privacy Policy Get Adobe Reader PALMETTO GBA A CELERIAN GROUP COMPANY			

View Reports

CAMER FOR MEDICARE A MEDICARD SERVI	28		TPAdministrator.com	Contact Us	My Profile Log Out Logged in as MO578408
Overview	Discarded Drug Program				
Discarde Reports	ed Drug Progr Reports	am			
Payments	P Number All	Refund I V All		~	
					Filter Reset
	Show 10 🗸 entries				
	P Number	Refund Period	Report Date		Download
	P8019	Q1 2023	12/31/2024		CSV
	P8019	Q2 2023	12/31/2024		
	P8019	Q3 2023	12/31/2024		CSV
	D9010	04 2022	10/21/2024		

Reports

2	AutoSave	Off 🗄	り、 (⁻ マ 11202024P8019Q12023	12312024 No	Label 🗸	𝒫 Search					Ģ) –	o x
	File Home	e Insert P	Page Layout Formulas Data Review	w View Au	tomate F	lelp Acroba	at				P	Comments	🖻 Share 🗸
	Paste S V Clipboard	🖽 🗸 🖉		eneral → 5 ~ % 9 .0 .00 .0 →0 Number 5	🔛 Conditio 🞲 Format 👿 Cell Styl		y → Inser Dele Form Cell	te v ↓v nat v 🞸 v	,○ ~ Sensit ~	ivity Add-ins		Create PDF k Share via Our bbe Acrobat	
В	9 ~	·] : [X 🗸]	$f_x \sim$										~
	А	В	С	D	E	F	G	Н	I.	J	К	L	M
1			HCPCS Long Description								Refund Amount Due		
	12/31/2024		INJECTION, TIGERMAB, 10 MG	12345	P8019	Initial		Q1	2023	· · · · · ·			
3			INJECTION, BEARULINE ACETATE, 10 MG		P8019	Initial		Q1	2023	· · · · · ·	1 A	02/28/2025	
4	12/31/2024	J0003	INJECTION, LIONZOLOMIDE, 1 MG	34567	P8019	Initial		Q1	2023	767.00	\$624.66	02/28/2025	
5													
6													
7													
8													
9 10		ļ,											
11													
12 13													
14													
15													
16													
10	< >	Sheet0	+										
Re	ady 😚 Acce	essibility: Good t	o go						교 Dis	splay Settings	▋		- + 100%

Payments

CENTERS TOT MEDICAR & MEDICAD SERVICES			TPAdministrator.com	m Contact Us	My Profile Log Out Logged in as MO578408
Overview	Discarded Drug Program				
Discarded	Drug Program	١			
Payments	Payable Pending	Submitted			
	Drug	P Number	Refund Peri	od	
	All	All	✓ All	~	
	Due Date				
	mm/dd/yyyy 🗖 🛛 mm,	/dd/yyyy 🗖			Filter Reset
	Show 10 🗸 entries				
	Drug = PNumber =	beler Refund ode Period	Payment Amount Failed 🔶 E	FT ID Due Date	Payment Initia Date Payme
	J0001 P8019 12	345 Q3 2023	\$228,423.45 D	PIX24123 02/28/20	11/19/2024

Payments Payable

nts						is or any other disc by the specified do			iate payment.
	Payable	Pending		nitted		-,			
	Drug		Р	Number		Refund Period			
	All		~ A	II	~	All	~		
	mm/dd	l/yyyy 🗖 🛛 n	mm/dd/yyyy						Filter Rese
	•	Payment succe			Payment	nts on the Pending	tab. Due Date	Payment Date	Filter Rese
	Show 10	Payment succe	essfully subr	nitted. View	Payment a Fa		Due Date	Date	Initiat
	Show 10	Payment succe entries P Number	essfully subr Labeler Code	nitted. View Refund Period	Payment Amount Fi	ailed 🔶 EFT ID	Due Date 02/28/2025	Date 12/03/2024	Initiat Payme
	Show 10 Drug J0001	Payment succe entries P Number P8019	essfully subr	nitted. View Refund Period Q3 2023	Payment Amount \$228,423.45	ailed 🔶 EFT ID DPIX24123	Due Date 02/28/2025 02/28/2025	Date 12/03/2024 12/03/2024	Initiat Payme

Payments Pending

Discarded	Drug Program				
Reports Payments	Payments Image: Stop payment function	on is available until approxim	ately 6:00 PM PT on the Payment	Process Date.	
	Payable Pending Drug All ~ Due Date mm/dd/yyyy mm/dd	Submitted P Number All /yyyy	Refund Period	~	Filter Reset
	Drug 🕈 P Number 🕈 C	abeler Refund Poriod	ending Payment Amount EFT ID \$2,775.73 DPIX24123	Payment Process Date	Due Date Stop Payment
		3456 Q4 2023	\$9,388.27 DPIX24123	11/20/2024 First Previo	02/28/2025
			C	Stop All Payment	Stop Payment

Payments Submitted

Reports	Payme	nts									
Payments	Payable	e Pending	J Submit	tted							
	Refund Peri	Refund Period									
	All		✓ Filter	Reset							
	Drug	PN	lumber	Status		Payment Initiated	Date				
	All	~ AI	· ~	All	~	mm/dd/yyyy	r	nm/dd/yyyy		Filter	Reset
	Show 10	 entries 									
	Show 10	P Number	Labeler Code	Refund Period	Payment Amount	Payment Initiated Date	÷	EFT ID	Due Date	\$	Status
							÷	EFT ID DPIX24123	Due Date 02/28/2025	*	
	Drug 🗍	P Number	Code	Period	Amount		÷				Status Success
	Drug 🗍 J0001	P Number	Code	Period Q4 2023	Amount 253467.61		÷	DPIX24123	02/28/2025	;	Status Success
	Drug J0001 J0004	P Number P8019 P8020	Code 12345 56789	Period Q4 2023 Q1 2023	Amount 253467.61 3276890.28		*	DPIX24123 DPIX24123	02/28/2025	5	Status Success Processing

TPA Resources

		TPAdministrator.com	Contact Us	My Profile I Logged in as M	og Out 0578408		
Overview Discarded Drug Program							
			Home	Archives Contact Us	CGDP Portal		
↑ TPA Programs -	Frequently Asked Questions (FAQ) - Listservs	-		Search for	٩		
Programs / Discarded Drug Program							
Discarded Drug	Discarded Drug Progra	m					
Program	Published 08/07/2024			1	ΑΑ ΑΑ		
Discarded Drug Reports Section 90004 of the Infrastructure Investment and Jobs Act (Pub. L. 117–58, November 15, 2021) requires manufacturers to provide a refund to CMS for certain discarded amounts from a refundable single-dose container or single-use package drug. The refund							
Disputes amount is the amount of discarded drug that exceeds an applicable percentage, which is required to be at least 10 percent, of total							
EFT Information	charges for the drug in a given calendar quarter						
ListservsRefundable single-dose container or single-use package drugs approved or licensed by FDA on or after November 15, 2021 are excluded from the definition of refundable single-dose container or single-use package, and thus, not subject to a refund, for the first 6 full							
Onboarding	calendar quarters following the date of first rep	•••••	· · · · ·		liist o luii		
User Guides							
Webinars							

CMS ASP Website

Discarded Drugs Page

NS .gov ∝	nters for Medicare & Medicaid Services About CMS Newsroom Data & Research
Medicare V	$\label{eq:rescaled} Medicald/CHIP \lor \qquad Marketplace & Private Insurance \lor \qquad Priorities \lor \qquad Training & Education \lor$
Medicare > Payment >	Medicare Part 8 Drug Average Sales Price > Discarded Drugs
1edicare Part B Dru werage Sales Price	, Discarded Drugs
ASP Reporting	Announcement
ASP Pricing Files	The Centers for Medicare & Medicaid Services (CMS) is implementing the retund collection portion of the Discarded Drug Program as required by Section 90004 of the Infrastructure Investment and Jobs Act (IIIA), which requires manufacturers to provide a retund to CMS for
ASP Billing Resources	certain discarded amounts from a refundable single-dose container or single-use package drug. CMS is working with a contractor, Palmetto GBA, to serve as a third-party administrator (TPA) of manufacture account creation in the Health Plan Management System (HPMS). In addition to
Vaccine Pricing	manufacturer account creation in the Heatth Plan Management System (HPMS). In adoution to supporting the Discarded Drug Program, HPMS supports several other programs for CMS, such as the Inflation Reduction Act's Medicate Prescription Drug Inflation Rebate Program.
ASP Regulations & Polic	Representatives from the TPA Support Center will be reaching out to manufacturers who are not yet onboarded into HPMS to begin the HPMS onboarding process. Once manufacturers have access to HPMS, they will be granted access to the Manufacturer Payment Portal (MPP) which is
Discarded Drugs	the invoicing and payment system.
ASP Education & Outre	
ASP Events	CMS will host a vehicer on Thursday, December 5, 2024, at 100 p.m. EST, for menufacturers of Refundable Drugs in the Macince Peth Broarded Drug Program and provide instructions on how to access provide an overview of the Discarded Drug Program and provide instructions on how to access Discarded Drug Refund Reports and pay refund amounts due in the Manufacturer Payment Portal (MPP) Signup now. Whinm Registration.
	Introduction
	Discarded Drug Refund
	Generatly, when a separately payled drug from a single-dote contenter or single-dep ackage is administered as individual envirolitien i Medicare Part II. Medicare payls the provider or facility for both administered and discarded amounts of the drug, up to the full labeled amount of the product. Section 500-04 of the II. (In the II. Int. 1.1.1.2.4.2.4.2.4.2.4.2.4.2.4.2.4.2.4.2.
	Questions
	What is a Refundable Drug? +

ASP Education & Outreach Page

MS.GOV Centers for Medicare & Medicaid Services About CMS Newsroom Data					
Medicare V Med	icaid/CHIP 🗸	Marketplace & Private I	nsurance V Priorities V Training & Educe	ation \checkmark	
dicare > Payment > Medica	re Part B Drug Average	Sales Price > ASP Education 8	Outreach		
care Part B Drug age Sales Price	ASP E	ducation & (Outreach		
Reporting	Refundable	Drugs in the Medicare Pa	December 5, 2024, at 1:00 p.m. EST, for manufacturer rt B Discarded Drug Program. This session is designed	to provide an	
Pricing Files		orts and pay refund amou	am and provide instructions on how to access Discardents nts due in the Manufacturer Payment Portal (MPP). Sig		
Billing Resources			P) data from manufacturers of Medicare Part B-covere , supplies, and products. Explore the resources below		
ine Pricing			ment limit calculation processes and other relevant to		
Regulations & Policy			Show Entries Filter On		
arded Drugs	Showing 1-10	of 17 entries	to bei bage 🔺		
Education & Outreach	Date 🗢	Title \$	Description \$	Format 🗢	
Events	2024-11- 12	Discarded Drug Program Overview	An overview of the Discarded Drug Program requires manufacturers of certain Part B Drugs to pay a refund to CMS for the portion of the drug that is discarded.	PDF	
	2024-06- 20	Manufacturers' Guide to Correcting Average Sales Price (ASP)	Guidance for manufacturers on what to do and what to expect if there is an error in previously submitted ASP data.	PDF	
	2024-06- 20	Average Sales Price (ASP) Restatement Policy Overview	A summary of CMS' Restatement Policy including details for corrections and criteria for issuing a restatement of ASP payment limits.	PDF	
	2024-05- 16	Part B Drug Payment Limits Overview	A fact sheet explaining the ASP payment limit calculation and other Medicare Part B drug payment methodologies.	PDF	
	2024-05- 03	Steps to Submit Part B Financial Data to CMS	A high-level overview of the key steps for manufacturers to register with the ASP Data Collection System and submit Part B drug product and financial data to CMS.	PDF	
	2024-03- 25	ASP Data Collection System Upgrade Release Notes - April 1st, 2024	A comprehensive list of the specific changes to various elements in the ASP Data Collection System effective April 1, 2024.	PDF	

ASP Events Page

	or Medicare & Medicaid Services About CMS Newsroom Data & Research Q
Medicare Y Med	licaid/CHIP Y Marketplace & Private Insurance Y Priorities Y Training & Education Y
Medicare > Payment > Medic	are Part B Drug Average Sales Price > ASP Events
edicare Part B Drug verage Sales Price	ASP Events
ASP Reporting	CMS will host a webinar on Thursday, December 5, 2024, at 1.00 p.m. EST, for manufacturers of Refundable Drugs in the Medicare Part B Discarded Drug Program. This session is designed to provide an overview of the Discarded Druge Program and provide instructions on how to access Discarded Drug
ASP Pricing Files	Webinar Registration.
SP Billing Resources	Materials from Past Events
/accine Pricing	✓ 2024
ASP Regulations & Policy	CMS held a webinar to provide an overview of the ASP Data Collection Module and ASP submission process for manufacturers of skin substitute products. This session was recorded and is now available
Discarded Drugs	for your reference: Skin Substitute Session (07/18/24)
ASP Education & Outreach	Webinar Recording:
ASP Events	 https://cms.zoomgov.com/rec/share/84/Vxd_gzwRWMq0rtosx76Hm45xtfytwEYFPcxyWfSmgM_ Ud0qExWNFskVL0xc.WBfnb5qid7_SIBUW?startTime=1726850276000
	Password:?v7qj1@K Presentation Slides (PDF)
	CMS held webinars to provide an overview of the updated ASP Data Collection Module available April 1, 2024. Those sessions were recorded and are now available for your reference:
	Submitter Session (03/21/2024)
	 Webinar Recording: https://cms.zoomgov.com/rec/share/YwFQ17AnaueaD_5xbUfNSECIvr- BxvY8JUI8Jw0F0kkPLCfSQBNnWsxD-GSkveyUdtTQzzBdJnYHJFSa
	Passcode: 0Y3+xi.c Presentation Slides
	Certifier Session (03/19/2024)
	 Webinar Recording: https://cms.zoomgov.com/rec/share/dNum4LRjtyLvg1HYL9rcUdCNsYj_je_sVnNTdVhQfD51bTWadDw6zoloey4z3qU28.fDEI36ef52KWRyAi_
	Passode: RBKVVT@B Presentation Stides
	Page Last Molfilez: 1020/02041104 AM

Program Overview

An overview of the Discarded Drug Program requires manufacturers of certain Part B Drugs to pay a refund to CMS for the portion of the drug that is discarded.

- Criteria
- Reporting
- Calculation
- Billing
- Payment
- Enforcement and Penalty



Discarded Drug Program Overview

Generally, when a separately payable drug from a single-dose container or single-use package is administered to an individual enrolled in Medicare Part B, Medicare pays the provider or facility for both administered and discarded amounts of the drug, up to the full labeled amount of the product. Section 90004 of the Infrastructure Investment and Jobs Act (IIJA) (Pub, L__117-58, November 15, 2021) amended section 1847A of the Social Security Act (the Act) by adding provisions that require manufacturers to provide a refund to CMS for certain discarded amounts of the amount of payment for discarded amounts of a refundable drug (described below) that exceeds an applicable percentage, which is required to be at least 10 percent of total charges for the drug in a given calendar quarter. For specific calculations for new refund quarters and updated refund quarters, refer to 42 CER 5414.940(c).

Criteria

Manufacturers required to refund CMS for discarded amounts are those that manufacture refundable single-dose container or single-use package drugs (hereinafter referred to as refundable drugs), which are defined as singlesource drugs, biologicals, or biosimilar biological products for which payment has been made under Medicare Part B and that are furnished from a single-dose container or single-use package. Exclusions from the definition of refundable drugs, as described in <u>42 CFR \$414,902</u>, and <u>87 FR 69719</u>, include:

- Radiopharmaceuticals (therapeutic or diagnostic) or imaging agents
- Certain drugs or biologicals requiring filtration during the preparation process (prior to dilution and administration) for which unused portions must be discarded after the filtration process
- Drugs approved or licensed by FDA on or after November 15, 2021, until the last day of the sixth full quarter for which the drug has been marketed (as reported to CMS) for the first reported sale for any NDCs of such drug

Reporting

CMS requires providers and suppliers to use the JW modifier on all claims for separately payable drugs with discarded drug amounts from single-use containers or single-use packages separately payable under Part B to identify and monitor billing and payment for discarded amounts of drugs. In submitting claims to Medicare, providers must indicate the number of billing units of the drug that were discarded using the JW modifier. Use of the JZ modifier is required on claims for drugs from single-dose containers or single-use packages separately payable under Part B when there are no discarded amounts. For more information on the JZ and JW modifiers, please review the <u>IW-IZ Modifiers FAO (PDP) document</u>.

Calculation

The refund amount is the amount by which the product of the number of discarded units and the payment limit exceeds the applicable percentage of the estimated total allowed charges for the drug for a given quarter, which is required to be at least 10 percent of total charges for the drug in a given calendar quarter (<u>42 CFR § 414.940</u>). Medicare Part B drug payment limits are published and effective on a quarterly basis. CMS uses the published payment limits to calculate the refund due for each new refund quarter by:

Step (1): Multiplying the total number of discarded drug units based on the JW modifier submitted on all
applicable claims for the quarter and the drug's payment limit, as determined under section 1847A(b)(1)(B) or
(C) of the Act, for the quarter,

Step (2): Multiplying the applicable percentage by the total allowed charges for the drug for the quarter, and
 Step (3): Subtracting the product calculated in step (2) from the product calculated in step (1).

step (3) subtracting the product calculated in step (2) from the product calculated in step (1).
 Please note: Applicable percentages may vary based on refundable drugs' unique circumstances and are described further in <u>42 CTRs 414.940(1)</u>. Manufacturers may apply for an adjustment to their drugs applicable percentage. Application instructions are provided on the <u>CMS Discarded Drugs website</u>.

Billing

Manufacturer reports will be issued through the Manufacturer Payment Portal (MPP). CMS will issue an annual report to all manufacturers of refundable drugs, which will include the total number of units discarded based on the JW modifier and the refund amount calculated for each quarter. Manufacturers have an opportunity to submit an error report to CMS within 30 days after receipt of their report.

Payment

Manufacturers will be able to pay any refunds due through the MPP. Payment for refund amounts specified in the refund report is due by December 31 of the year in which the report is sent, except for the initial Report for calendar quarters in 2023, which is due no later than February 28, 2025. If an error report is pending, payment will be due on the due date of the initial report or no later than 30 days after the error report has been resolved, whichever is later. (42 CFR 5414.940/b)(1) and (2)).

Enforcement and Penalty

Manufacturers of refundable drugs who do not comply with the requirement set forth at 42 CFR § 414.940(b) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(b) and 940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of the assessed refund obligation as described in 42 CFR § 414.940(c) are subject to a civil money penalty of 125 percent of 12

For more information visit: <u>CMS Discarded Drugs Website</u> Contact us at: <u>DiscardedDrugs@cms.hhs.gov</u> Published: November 2024

Checklist

- Instructions on how to complete key program tasks
- Support information



Discarded Drug Program Manufacturer Quick Reference

Manufacturers play an active role in the discarded drug refund calculation process, from timely input of quarterly data to accurate record keeping. This quick reference guide of highlevel steps is designed to aid manufacturers during the discarded drug refund calculation process and to ensure compliance with legislation to avoid civil monetary penalties. For more information, visit the CMS Discarded Drugs <u>website</u>. Contact us at: <u>DiscardedDrugs@cms.hhs.gov</u>.



Request a P Number

CMS uses P Numbers to identify manufacturer accounts in the Health Plan Management System (HPMS) for various programs such as the Inflation Reduction Act's Medicare Prescription Drug Inflation Rebate Program and the Medicare Part B Discarded Drug Program. If you are new to the Discarded Drug Program, and have not been issued a P Number, please submit the following information via email to <u>DiscardedDrugs@cms.hhs.gov</u> to request a P Number:

- o Manufacturer Legal Name
- Data Universal Numbering System (DUNS) Number
- Employer Identification Number (EIN)
- Primary Contact First and Last Name
- · Primary Contact Email Address
- Primary Contact Phone Number
- Subject Line of the Email Should Read "[Manufacturer Name] Request for P Number"

After you send your request, CMS will contact you should we require any additional information to issue a P Number. Once your P Number is issued, a representative from Palmetto GBA, a contractor serving as CMS' third-party administrator (TPA) for the invoicing and payment processes, will reach out to begin the HPMS onboarding process.

Error Reports

Manufacturers have 30 days after receipt of their refund report(s) to assert that there have been one or more errors in the report. To submit a dispute for each asserted error, provide the following information in a written request to DiscardedDrugs@cms.hhs.gov:

- Manufacturer name and address
- Name, telephone, and email address of one or more employees of the manufacturer

For a Mathematical Calculation Error	For Any Other Asserted Error				
 The specific calculation element(s) that the manufacturer disputes The proposed corrected calculation 	 An explanation of the nature of the error How the error affects the refund calculation An explanation of why the manufacturer believes that an error occurred The proposed correction to the error An explanation of why CMS should use the proposed corrected data 				

What's Next?

- ✓ Ensure you have a P Number
- ✓ Select your Program Designation (Part B or Part B and Part D) in HPMS
- ✓ Add your Program Contact Information in HPMS
- \checkmark TPA will reach out in mid-December to enroll you into MPP
- ✓ Ensure you have access to MPP by logging in after enrollment
- ✓ Add EFT information before 11:59 p.m. on December 27, 2024
- ✓ Log in to MPP by December 31, 2024
- ✓ View and pay refund amounts due by February 28, 2025





Closing Remarks

- <u>Discarded Drugs webpage</u>
- Technical Support (TPA)
 - tpaoperations@tpadministrator.com
 - 1-877-534-2772 (Option 1)
- Feedback and Other Questions
 - <u>DiscardedDrugs@cms.hhs.gov</u>

